STACEY BERG

Concepts (344)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
31
2021
1691
2.470
Why?
Neoplasms
35
2024
2790
2.130
Why?
Leukemia
10
2019
372
1.030
Why?
Antineoplastic Combined Chemotherapy Protocols
10
2024
1251
0.880
Why?
Pyrimidines
6
2024
373
0.830
Why?
Thalidomide
3
2011
36
0.780
Why?
Neuroblastoma
7
2021
526
0.750
Why?
Arabinonucleosides
3
2006
32
0.750
Why?
Protein Kinase Inhibitors
6
2021
541
0.720
Why?
Azepines
3
2019
63
0.670
Why?
Medical Oncology
4
2010
216
0.660
Why?
Vincristine
2
2021
193
0.640
Why?
Meningeal Neoplasms
7
2011
185
0.630
Why?
Neoplasm Recurrence, Local
13
2024
1140
0.630
Why?
Maximum Tolerated Dose
14
2024
163
0.550
Why?
Child
50
2024
24421
0.550
Why?
Salvage Therapy
5
2019
192
0.540
Why?
Antineoplastic Agents, Alkylating
4
2010
100
0.530
Why?
Child, Preschool
38
2024
14027
0.520
Why?
Drug Therapy
1
2016
87
0.520
Why?
Antineoplastic Agents, Phytogenic
2
2015
101
0.520
Why?
Piperazines
4
2024
240
0.510
Why?
Pharmaceutical Preparations
1
2016
79
0.500
Why?
Drugs, Essential
3
2023
7
0.490
Why?
Macaca mulatta
12
2011
491
0.480
Why?
Benzimidazoles
2
2022
133
0.480
Why?
Dacarbazine
3
2011
95
0.470
Why?
Central Nervous System Neoplasms
4
2024
197
0.460
Why?
Oxygenases
1
2014
4
0.460
Why?
Daunorubicin
1
2014
27
0.460
Why?
Histone Deacetylase Inhibitors
3
2012
75
0.460
Why?
Glutathione S-Transferase pi
1
2014
25
0.460
Why?
O(6)-Methylguanine-DNA Methyltransferase
3
2009
20
0.460
Why?
Peripheral Nervous System Diseases
1
2015
122
0.450
Why?
Adolescent
39
2024
19363
0.450
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
2020
783
0.450
Why?
Microtubule-Associated Proteins
1
2015
245
0.440
Why?
Decision Support Techniques
1
2016
290
0.430
Why?
Drug Resistance, Neoplasm
9
2024
723
0.430
Why?
Area Under Curve
12
2021
316
0.420
Why?
Antibiotics, Antineoplastic
3
2014
128
0.420
Why?
Clinical Trials, Phase I as Topic
2
2010
61
0.420
Why?
Young Adult
21
2024
9053
0.390
Why?
Hydroxamic Acids
1
2012
56
0.390
Why?
Guanine
3
2011
61
0.390
Why?
Camptothecin
3
2008
73
0.390
Why?
Enzyme Inhibitors
5
2009
581
0.380
Why?
Doxorubicin
2
2014
290
0.380
Why?
Informed Consent
3
2009
333
0.380
Why?
Poly(ADP-ribose) Polymerase Inhibitors
2
2024
30
0.380
Why?
Sarcoma, Ewing
3
2022
110
0.370
Why?
Patient Participation
3
2010
220
0.350
Why?
Humans
68
2024
125189
0.350
Why?
Male
49
2024
61525
0.350
Why?
Body Composition
2
2014
521
0.340
Why?
Obesity
2
2014
2248
0.340
Why?
Dose-Response Relationship, Drug
10
2018
1697
0.340
Why?
Metabolic Clearance Rate
5
2014
144
0.340
Why?
Myelodysplastic Syndromes
1
2010
138
0.320
Why?
Antimetabolites, Antineoplastic
4
2020
183
0.310
Why?
Chromatography, High Pressure Liquid
8
2011
344
0.310
Why?
Carboxylic Acids
1
2008
25
0.310
Why?
Medulloblastoma
2
2012
325
0.310
Why?
Rhabdomyosarcoma
2
2022
192
0.310
Why?
Infant
21
2024
12516
0.310
Why?
Boronic Acids
2
2005
46
0.300
Why?
Cyclophosphamide
2
2008
417
0.300
Why?
Physician-Patient Relations
2
2009
429
0.300
Why?
Pyrazines
2
2005
73
0.300
Why?
Oligopeptides
1
2008
118
0.300
Why?
Cyclin-Dependent Kinase 6
2
2024
41
0.280
Why?
Cyclin-Dependent Kinase 4
2
2024
59
0.280
Why?
Clinical Trials as Topic
2
2009
1099
0.280
Why?
Phthalazines
2
2024
13
0.270
Why?
Female
42
2024
66806
0.270
Why?
Polymorphism, Single Nucleotide
1
2015
2637
0.260
Why?
Infusions, Intravenous
8
2005
554
0.260
Why?
Indoles
2
2004
190
0.260
Why?
Topotecan
3
2012
48
0.240
Why?
Leukemia, T-Cell
1
2005
11
0.240
Why?
Ethics, Medical
2
2007
396
0.240
Why?
Protease Inhibitors
1
2005
96
0.240
Why?
DNA Repair
3
2024
585
0.240
Why?
Cell Line, Tumor
6
2018
3348
0.230
Why?
Cyclopentanes
1
2024
20
0.230
Why?
Cyclin D1
1
2004
111
0.230
Why?
Depsipeptides
1
2004
10
0.220
Why?
Cyclins
1
2004
101
0.220
Why?
Carbazoles
1
2004
33
0.220
Why?
Peptides, Cyclic
1
2004
55
0.220
Why?
Cisplatin
2
2004
249
0.220
Why?
Parents
3
2009
1024
0.210
Why?
Rhabdoid Tumor
1
2023
46
0.210
Why?
Glioma
2
2022
492
0.210
Why?
Pyridines
1
2024
230
0.200
Why?
Methotrexate
2
2020
334
0.200
Why?
Proto-Oncogene Proteins B-raf
1
2024
188
0.200
Why?
Adult
19
2024
29628
0.190
Why?
TOR Serine-Threonine Kinases
1
2024
429
0.190
Why?
Models, Theoretical
1
2004
363
0.190
Why?
Treatment Outcome
14
2020
12392
0.190
Why?
Dactinomycin
1
2021
66
0.180
Why?
Maytansine
1
2020
3
0.180
Why?
Neurofibrosarcoma
1
2020
5
0.180
Why?
Injections, Spinal
6
2011
127
0.180
Why?
Pulmonary Blastoma
1
2020
11
0.170
Why?
Sarcoma, Synovial
1
2020
21
0.170
Why?
Sodium Bicarbonate
1
2020
55
0.170
Why?
Drug Synergism
3
2009
228
0.170
Why?
Protein-Tyrosine Kinases
2
2019
211
0.160
Why?
Drug Interactions
3
2012
257
0.160
Why?
National Cancer Institute (U.S.)
3
2024
32
0.160
Why?
Cerebrospinal Fluid
3
2004
93
0.160
Why?
Wilms Tumor
1
2020
115
0.160
Why?
Research Subjects
1
2019
54
0.160
Why?
Drug Administration Schedule
6
2018
729
0.150
Why?
Antineoplastic Agents, Immunological
1
2020
115
0.150
Why?
Lymphoma, Non-Hodgkin
1
2020
164
0.150
Why?
Antibodies, Monoclonal
2
2024
1033
0.150
Why?
Topoisomerase I Inhibitors
2
2011
16
0.150
Why?
Bone Neoplasms
2
2019
426
0.150
Why?
Research Personnel
1
2019
117
0.150
Why?
Inhibitory Concentration 50
3
2014
77
0.150
Why?
Furans
1
2018
29
0.150
Why?
Ketones
1
2018
26
0.150
Why?
Recurrence
3
2019
1420
0.140
Why?
Health Services Accessibility
2
2023
606
0.140
Why?
Cell Cycle Proteins
2
2019
656
0.140
Why?
Aurora Kinase A
1
2018
39
0.140
Why?
Animals
16
2019
34232
0.140
Why?
Hodgkin Disease
1
2020
292
0.140
Why?
Cell Survival
2
2012
813
0.140
Why?
Health Policy
1
2019
213
0.130
Why?
Mass Spectrometry
3
2006
332
0.130
Why?
Brain Neoplasms
2
2004
1216
0.130
Why?
Health Care Rationing
1
2016
58
0.120
Why?
Palliative Care
1
2019
433
0.120
Why?
Pediatrics
3
2010
1152
0.120
Why?
Deoxycytidine
2
2007
78
0.120
Why?
Molecular Targeted Therapy
2
2022
361
0.110
Why?
Drug Screening Assays, Antitumor
1
2014
94
0.110
Why?
Prodrugs
2
2006
59
0.110
Why?
Glioblastoma
1
2018
330
0.110
Why?
Absorptiometry, Photon
1
2014
178
0.110
Why?
Separase
1
2014
29
0.110
Why?
Clinical Decision-Making
1
2016
264
0.110
Why?
Biomedical Research
1
2019
519
0.110
Why?
Pregnancy Complications, Neoplastic
1
2014
62
0.110
Why?
Mutation
2
2024
5845
0.110
Why?
Pharmacogenetics
1
2014
184
0.110
Why?
Tumor Cells, Cultured
2
2005
1065
0.110
Why?
Practice Guidelines as Topic
2
2017
1272
0.100
Why?
Injections, Intravenous
3
2008
249
0.100
Why?
Neoplasm Staging
2
2008
1275
0.100
Why?
Haplotypes
1
2014
522
0.100
Why?
Meningitis, Aseptic
1
2012
13
0.100
Why?
Aurora Kinase B
1
2012
8
0.100
Why?
Aurora Kinases
1
2012
32
0.100
Why?
Pyrroles
2
2024
182
0.100
Why?
Mitogen-Activated Protein Kinases
2
2024
207
0.100
Why?
Models, Statistical
1
2014
471
0.090
Why?
Survival Rate
4
2019
2062
0.090
Why?
Genomics
1
2019
1499
0.090
Why?
Brain Stem Neoplasms
1
2011
42
0.090
Why?
Polymorphism, Genetic
1
2014
816
0.090
Why?
Half-Life
4
2021
158
0.090
Why?
Prognosis
4
2019
4645
0.090
Why?
Lung Neoplasms
1
2021
1659
0.090
Why?
Organoplatinum Compounds
1
2010
28
0.090
Why?
Blood-Brain Barrier
2
2018
141
0.090
Why?
Disease Models, Animal
4
2019
4395
0.090
Why?
Altruism
1
2010
23
0.090
Why?
United States
6
2024
10915
0.090
Why?
Immunity, Cellular
1
2010
206
0.080
Why?
Survival Analysis
3
2020
1506
0.080
Why?
DNA Mismatch Repair
1
2009
50
0.080
Why?
Apoptosis
3
2018
1806
0.080
Why?
Drug Discovery
1
2010
171
0.080
Why?
Tissue Distribution
2
2019
391
0.080
Why?
Acyclovir
1
2008
45
0.080
Why?
Bortezomib
2
2005
70
0.080
Why?
Body Mass Index
1
2014
1565
0.070
Why?
Valine
1
2008
115
0.070
Why?
Carmustine
1
2008
26
0.070
Why?
Confidentiality
1
2008
99
0.070
Why?
Follow-Up Studies
4
2019
5176
0.070
Why?
Human Experimentation
1
2007
36
0.070
Why?
Ethics, Research
1
2007
51
0.070
Why?
Carboplatin
2
2004
76
0.070
Why?
Genome-Wide Association Study
1
2014
1689
0.070
Why?
Administration, Intravenous
2
2020
143
0.070
Why?
Erythropoietin
1
2007
105
0.070
Why?
DNA Damage
2
2024
513
0.070
Why?
Benzamides
2
2023
109
0.070
Why?
Valproic Acid
1
2007
165
0.060
Why?
Immunocompromised Host
1
2008
294
0.060
Why?
Proto-Oncogene Proteins c-mdm2
1
2006
80
0.060
Why?
Adenine Nucleotides
1
2005
41
0.060
Why?
Risk
1
2007
756
0.060
Why?
Xenograft Model Antitumor Assays
2
2019
889
0.060
Why?
Administration, Oral
3
2018
684
0.060
Why?
Imidazoles
1
2006
203
0.060
Why?
Proto-Oncogene Proteins c-bcl-2
1
2005
173
0.060
Why?
Cyclin D3
1
2004
10
0.060
Why?
Cyclin D2
1
2004
14
0.060
Why?
Cyclin D
1
2024
6
0.060
Why?
Proteasome Inhibitors
1
2004
60
0.060
Why?
NEDD8 Protein
1
2024
11
0.060
Why?
Heat-Shock Proteins
1
2005
195
0.060
Why?
Prospective Studies
2
2021
6153
0.060
Why?
Thiophenes
1
2005
70
0.060
Why?
Retinoblastoma Protein
1
2004
79
0.060
Why?
Bridged Bicyclo Compounds, Heterocyclic
1
2024
39
0.060
Why?
BRCA2 Protein
1
2024
45
0.060
Why?
Cyclin-Dependent Kinases
1
2004
86
0.060
Why?
BRCA1 Protein
1
2024
69
0.060
Why?
Ataxia Telangiectasia Mutated Proteins
1
2024
96
0.060
Why?
Quinazolines
1
2005
175
0.050
Why?
Aminopyridines
1
2024
55
0.050
Why?
SMARCB1 Protein
1
2023
37
0.050
Why?
Neoplasm Proteins
1
2008
667
0.050
Why?
Anemia
1
2007
339
0.050
Why?
Enhancer of Zeste Homolog 2 Protein
1
2023
62
0.050
Why?
Phenylacetates
1
2003
23
0.050
Why?
Nuclear Proteins
2
2023
1265
0.050
Why?
Drug Administration Routes
1
2003
32
0.050
Why?
Phosphatidylinositol 3-Kinases
1
2024
335
0.050
Why?
Ipilimumab
1
2022
62
0.050
Why?
Physicians
1
2009
587
0.050
Why?
MAP Kinase Signaling System
1
2024
314
0.050
Why?
Germ-Line Mutation
1
2024
333
0.050
Why?
DNA Helicases
1
2023
231
0.050
Why?
Mixed Function Oxygenases
1
2002
30
0.050
Why?
Glutamine
1
2003
215
0.050
Why?
Cell Cycle
1
2004
617
0.050
Why?
Europe
1
2023
354
0.050
Why?
Mitogen-Activated Protein Kinase Kinases
1
2022
89
0.050
Why?
Phenytoin
1
2002
63
0.050
Why?
DNA-Binding Proteins
2
2024
2048
0.050
Why?
Lymphoma
1
2005
323
0.050
Why?
Vascular Endothelial Growth Factor A
1
2024
412
0.050
Why?
Proto-Oncogene Proteins
1
2004
547
0.050
Why?
Cytochrome P-450 Enzyme System
1
2002
135
0.040
Why?
Proto-Oncogene Proteins p21(ras)
1
2022
158
0.040
Why?
Clinical Protocols
1
2022
240
0.040
Why?
CD56 Antigen
1
2020
26
0.040
Why?
Decision Making
1
2006
656
0.040
Why?
Biomarkers, Tumor
2
2019
1496
0.040
Why?
Response Evaluation Criteria in Solid Tumors
1
2020
8
0.040
Why?
Surveys and Questionnaires
1
2010
3729
0.040
Why?
DNA Repair Enzymes
2
2011
39
0.040
Why?
DNA Modification Methylases
2
2011
44
0.040
Why?
Pyrimidinones
1
2019
49
0.040
Why?
Drugs, Generic
1
2019
13
0.040
Why?
Community Participation
1
2019
44
0.040
Why?
Sodium
1
2020
297
0.040
Why?
Retreatment
1
2019
89
0.040
Why?
Anticonvulsants
1
2002
381
0.040
Why?
Risk Assessment
2
2005
3465
0.040
Why?
Patient Rights
1
2019
51
0.040
Why?
Focus Groups
1
2019
198
0.040
Why?
Family
2
2016
566
0.040
Why?
Combined Modality Therapy
3
2008
1242
0.040
Why?
Multimodal Imaging
1
2019
114
0.040
Why?
Algorithms
1
2005
1629
0.040
Why?
Microtubules
1
2018
189
0.030
Why?
Time Factors
2
2004
6338
0.030
Why?
Pyrazoles
1
2019
305
0.030
Why?
Immunophenotyping
1
2018
329
0.030
Why?
Neoplasm Grading
1
2018
272
0.030
Why?
Tumor Suppressor Proteins
2
2011
468
0.030
Why?
Dexamethasone
2
2012
276
0.030
Why?
Flow Cytometry
1
2018
797
0.030
Why?
United States Food and Drug Administration
1
2016
150
0.030
Why?
Patient Safety
1
2019
401
0.030
Why?
Interdisciplinary Communication
1
2016
130
0.030
Why?
Proportional Hazards Models
2
2011
1360
0.030
Why?
Pilot Projects
1
2018
1396
0.030
Why?
Rhodamines
1
2014
23
0.030
Why?
Immunohistochemistry
1
2018
1693
0.030
Why?
Infant, Newborn
3
2017
8233
0.030
Why?
Hydrolysis
1
2014
161
0.030
Why?
Transcription Factors
1
2023
2593
0.030
Why?
High-Throughput Screening Assays
1
2014
97
0.030
Why?
Neoplasm Transplantation
1
2014
376
0.030
Why?
Mice
3
2019
17631
0.030
Why?
Infusions, Intraventricular
1
2012
13
0.030
Why?
Microscopy, Fluorescence
1
2014
330
0.030
Why?
Antibodies
1
2014
374
0.020
Why?
Retrospective Studies
3
2020
16353
0.020
Why?
Phosphoproteins
1
2014
418
0.020
Why?
Ki-67 Antigen
1
2011
113
0.020
Why?
Age Factors
2
2008
2823
0.020
Why?
Peptides
1
2014
811
0.020
Why?
Health Insurance Portability and Accountability Act
1
2008
19
0.020
Why?
State Government
1
2008
29
0.020
Why?
Biomarkers
1
2018
3091
0.020
Why?
Government Regulation
1
2008
41
0.020
Why?
Kaplan-Meier Estimate
1
2011
1056
0.020
Why?
Drug Therapy, Combination
1
2011
1172
0.020
Why?
Darbepoetin alfa
1
2007
15
0.020
Why?
Pharmacokinetics
1
2007
16
0.020
Why?
Microsatellite Instability
1
2007
36
0.020
Why?
Radiotherapy Dosage
1
2008
183
0.020
Why?
Bone Marrow Diseases
1
2008
41
0.020
Why?
DNA, Neoplasm
1
2008
302
0.020
Why?
Hematinics
1
2007
55
0.020
Why?
Cell Proliferation
1
2014
2311
0.020
Why?
HCT116 Cells
1
2006
55
0.020
Why?
Stem Cell Transplantation
1
2008
237
0.020
Why?
Hemoglobins
1
2007
311
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2008
259
0.020
Why?
Pulse Therapy, Drug
1
2004
8
0.010
Why?
Middle Aged
3
2014
26927
0.010
Why?
Biological Availability
1
2004
137
0.010
Why?
Meningitis
1
2005
98
0.010
Why?
Imatinib Mesylate
1
2004
46
0.010
Why?
Probability
1
2004
320
0.010
Why?
Biotransformation
1
2003
50
0.010
Why?
Spectrophotometry, Ultraviolet
1
2003
45
0.010
Why?
Ultraviolet Rays
1
2004
203
0.010
Why?
Catheters, Indwelling
1
2004
154
0.010
Why?
Practice Patterns, Physicians'
1
2008
731
0.010
Why?
Injections, Intraventricular
1
2002
63
0.010
Why?
Feasibility Studies
1
2005
761
0.010
Why?
Ondansetron
1
2002
10
0.010
Why?
Tumor Suppressor Protein p53
1
2006
723
0.010
Why?
Pineal Gland
1
2002
18
0.010
Why?
Pinealoma
1
2002
19
0.010
Why?
Melphalan
1
2002
49
0.010
Why?
Phenobarbital
1
2002
36
0.010
Why?
Enzyme Induction
1
2002
104
0.010
Why?
Etoposide
1
2002
115
0.010
Why?
Breast Neoplasms
1
2014
2513
0.010
Why?
Cytochrome P-450 CYP3A
1
2002
59
0.010
Why?
Cranial Irradiation
1
2002
67
0.010
Why?
Pregnancy
1
2014
7207
0.010
Why?
Multivariate Analysis
1
2004
1438
0.010
Why?
Protein Binding
1
2004
1756
0.010
Why?
Cohort Studies
1
2008
4817
0.010
Why?
Models, Biological
1
2003
1460
0.010
Why?
Seizures
1
2002
872
0.010
Why?
Disease Progression
1
2002
2067
0.010
Why?
Hematopoietic Stem Cell Transplantation
1
2002
1203
0.010
Why?
BERG's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (344)
Explore
_
Co-Authors (42)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_